Skip to content
DataLookout
Menu

RiMO-HNC-NEO1NCT07732634

Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Lead sponsor: University of Illinois at Chicago to University of Illinois Chicago
    • Eligibility criteria expanded, about 35 words
    • Primary completion pushed from Aug 2029 to Nov 2029
    • Study completion pushed from Aug 2031 to Nov 2031
    • Start date changed from estimate of Aug 2026 to Nov 9, 2026
    • Secondary endpoints: 7 to 6
    • Site details revised
    • Study title shortened, about 6 words
    • Study description shortened, about 5 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Efficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by major pathologic response (i.e., percentage of participants whose tumors shrink).
Timeframe: At surgical resection

Secondary (6)

Progression-free survival rate as defined by the number of patients whose disease progresses since the start of treatment
Overall survival rate as defined by the number of deaths among participants
Number of Grade 3 and Grade 4 toxicities experienced by participants as defined by CTCAE version 6
To assess the rate of Pathological Complete Response (pCR)
To assess surgical outcomes through margin measurements at surgical resection
Show 1 moreShow less
To evaluate the change in disease staging as assessed by the proportion of patients who have a reduction in the size or extent of tumor

Arms and interventions

RiMO-301 combined with radiotherapy and pembrolizumab followed by surgical resectionExperimental

RiMO-301 will be injected intratumorally once prior to radiotherapy. Radiotherapy will start within 1 day after the RiMO-301 injection for 5 fractions of 4-5 Grays per fraction over a period of 5-15 days. Pembrolizumab 200 mg will be administered intravenously every 3 weeks (Q3W) within the first dose given on the same day as the RiMO-301 injection (+/-1 day). Pembrolizumab will continue for 2 cycles (1 cycle = 21 days). Surgical resection of the tumor will occur after the completion of neoadjuvant therapy.

Drugs: RiMO-301, Pembrolizumab

Radiation: Radiation

Procedures: Surgical resection

Sites

1 site in 1 country

  • University of Illinois at ChicagoChicago, Illinois, United States